Cargando…
Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
S. Karger AG
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801177/ https://www.ncbi.nlm.nih.gov/pubmed/36589724 http://dx.doi.org/10.1159/000526388 |
| _version_ | 1784861446236012544 |
|---|---|
| author | Endo, Kei Kuroda, Hidekatsu Oikawa, Takayoshi Ito, Yuma Abe, Tamami Kooka, Youhei Kakisaka, Keisuke Miyasaka, Akio Sugai, Tamotsu Matsumoto, Takayuki |
| author_facet | Endo, Kei Kuroda, Hidekatsu Oikawa, Takayoshi Ito, Yuma Abe, Tamami Kooka, Youhei Kakisaka, Keisuke Miyasaka, Akio Sugai, Tamotsu Matsumoto, Takayuki |
| author_sort | Endo, Kei |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9801177 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | S. Karger AG |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98011772022-12-31 Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab Endo, Kei Kuroda, Hidekatsu Oikawa, Takayoshi Ito, Yuma Abe, Tamami Kooka, Youhei Kakisaka, Keisuke Miyasaka, Akio Sugai, Tamotsu Matsumoto, Takayuki Liver Cancer Letter to the Editor S. Karger AG 2022-08-16 /pmc/articles/PMC9801177/ /pubmed/36589724 http://dx.doi.org/10.1159/000526388 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. |
| spellingShingle | Letter to the Editor Endo, Kei Kuroda, Hidekatsu Oikawa, Takayoshi Ito, Yuma Abe, Tamami Kooka, Youhei Kakisaka, Keisuke Miyasaka, Akio Sugai, Tamotsu Matsumoto, Takayuki Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab |
| title | Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab |
| title_full | Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab |
| title_fullStr | Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab |
| title_full_unstemmed | Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab |
| title_short | Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab |
| title_sort | immune checkpoint inhibitor-related pneumonia in unresectable hepatocellular carcinoma: two fatal cases under atezolizumab plus bevacizumab |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801177/ https://www.ncbi.nlm.nih.gov/pubmed/36589724 http://dx.doi.org/10.1159/000526388 |
| work_keys_str_mv | AT endokei immunecheckpointinhibitorrelatedpneumoniainunresectablehepatocellularcarcinomatwofatalcasesunderatezolizumabplusbevacizumab AT kurodahidekatsu immunecheckpointinhibitorrelatedpneumoniainunresectablehepatocellularcarcinomatwofatalcasesunderatezolizumabplusbevacizumab AT oikawatakayoshi immunecheckpointinhibitorrelatedpneumoniainunresectablehepatocellularcarcinomatwofatalcasesunderatezolizumabplusbevacizumab AT itoyuma immunecheckpointinhibitorrelatedpneumoniainunresectablehepatocellularcarcinomatwofatalcasesunderatezolizumabplusbevacizumab AT abetamami immunecheckpointinhibitorrelatedpneumoniainunresectablehepatocellularcarcinomatwofatalcasesunderatezolizumabplusbevacizumab AT kookayouhei immunecheckpointinhibitorrelatedpneumoniainunresectablehepatocellularcarcinomatwofatalcasesunderatezolizumabplusbevacizumab AT kakisakakeisuke immunecheckpointinhibitorrelatedpneumoniainunresectablehepatocellularcarcinomatwofatalcasesunderatezolizumabplusbevacizumab AT miyasakaakio immunecheckpointinhibitorrelatedpneumoniainunresectablehepatocellularcarcinomatwofatalcasesunderatezolizumabplusbevacizumab AT sugaitamotsu immunecheckpointinhibitorrelatedpneumoniainunresectablehepatocellularcarcinomatwofatalcasesunderatezolizumabplusbevacizumab AT matsumototakayuki immunecheckpointinhibitorrelatedpneumoniainunresectablehepatocellularcarcinomatwofatalcasesunderatezolizumabplusbevacizumab |